New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Pfizer

Status and phase: Completed; Phase 3

Conditions: Gram-positive Bacterial Infections; Community Acquired Infections; Pneumonia, Pneumococcal

Treatments: Drug: Antibiotic

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035269

A5951056

M12600071

Details and patient eligibility

About

This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)

Enrollment: 230 patients

Sex: All

Ages: 13+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

• Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia.
• The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment.

Exclusion Criteria:

• Patients cannot have taken more than one day of another antibiotic before entering this study.
• Patients with HIV and a low CD4 count are excluded.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)